Compare Huntington Bancshares Incorporated (HBAN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Novavax Inc — how do they compare? Huntington Bancshares Incorporated trades at $18.1 (market cap $36.62B), while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: Huntington Bancshares Incorporated is far larger — about 28.2× Novavax Inc's market cap, and Huntington Bancshares Incorporated pays a 3.43% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| HBAN | NVAX | |
|---|---|---|
Market Cap | $36.62B | $1.30B |
Sector | Financials | Health |
52-Week High | $19.27 | $11.19 |
52-Week Low | $15.02 | $6.22 |
Dividend Yield | 3.43% | — |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.07, down 0.99% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported Q1 2026 EPS of $0.25, beating expectations, with revenue growth to $8.13 billion in 2025. Recent news highlights expansion in Texas and a strong fintech partnership award.
HBAN presents a mixed outlook; analyst consensus is a Buy with a $20.25 price target, implying upside, but risks include integration challenges from acquisitions and competitive pressures in regional banking. Earnings growth and margin stability are key catalysts, though debt levels have risen steadily.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
